← Back to Search

Unknown

AB-2004 for Autism Spectrum Disorder

Phase 2
Waitlist Available
Research Sponsored by Axial Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is testing AB-2004 to see if it can safely and effectively reduce irritability in people with autism spectrum disorder by changing their gut bacteria.

Eligible Conditions
  • Autism Spectrum Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AB-2004Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Axial Therapeutics, Inc.Lead Sponsor

Media Library

AB-2004 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT04895215 — Phase 2
Autism Spectrum Disorder Research Study Groups: AB-2004, Placebo
Autism Spectrum Disorder Clinical Trial 2023: AB-2004 Highlights & Side Effects. Trial Name: NCT04895215 — Phase 2
AB-2004 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04895215 — Phase 2
~37 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top